BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taylor RP, Lindorfer MA. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol 2016;28:309-16. [PMID: 27009480 DOI: 10.1016/j.smim.2016.03.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Luo S, Wang M, Wang H, Hu D, Zipfel PF, Hu Y. How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application. Front Immunol 2020;11:593610. [PMID: 33193442 DOI: 10.3389/fimmu.2020.593610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, Brugarolas J, Wang T, Karbowniczek M, Markiewski MM. Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma. J Immunol 2020;205:3218-29. [PMID: 33158953 DOI: 10.4049/jimmunol.2000511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Bahri R, Kiss O, Prise I, Garcia-rodriguez KM, Atmoko H, Martínez-gómez JM, Levesque MP, Dummer R, Smith MP, Wellbrock C, Bulfone-paus S. Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. Front Immunol 2022;13:861545. [DOI: 10.3389/fimmu.2022.861545] [Reference Citation Analysis]
4 Jefferis R. Recombinant Proteins and Monoclonal Antibodies. In: Rapp E, Reichl U, editors. Advances in Glycobiotechnology. Cham: Springer International Publishing; 2021. pp. 281-318. [DOI: 10.1007/10_2017_32] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
6 Macor P, Capolla S, Tedesco F. Complement as a Biological Tool to Control Tumor Growth. Front Immunol 2018;9:2203. [PMID: 30319647 DOI: 10.3389/fimmu.2018.02203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
7 Parsons ES, Stanley GJ, Pyne ALB, Hodel AW, Nievergelt AP, Menny A, Yon AR, Rowley A, Richter RP, Fantner GE, Bubeck D, Hoogenboom BW. Single-molecule kinetics of pore assembly by the membrane attack complex. Nat Commun 2019;10:2066. [PMID: 31061395 DOI: 10.1038/s41467-019-10058-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
8 Shalapour S, Karin M. The neglected brothers come of age: B cells and cancer. Semin Immunol 2021;:101479. [PMID: 34215491 DOI: 10.1016/j.smim.2021.101479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ricklin D, Lambris JD. Complement therapeutics. Semin Immunol 2016;28:205-7. [PMID: 27522923 DOI: 10.1016/j.smim.2016.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
10 Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018;18:5-18. [PMID: 28920587 DOI: 10.1038/nri.2017.97] [Cited by in Crossref: 157] [Cited by in F6Publishing: 155] [Article Influence: 31.4] [Reference Citation Analysis]
11 Schmaljohn AL, Orlandi C, Lewis GK. Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models. Front Immunol 2019;10:1602. [PMID: 31379822 DOI: 10.3389/fimmu.2019.01602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 O'Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N. Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers (Basel) 2021;13:1209. [PMID: 33802004 DOI: 10.3390/cancers13061209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jain A, Ramasamy K. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clinical Lymphoma Myeloma and Leukemia 2020;20:572-87. [DOI: 10.1016/j.clml.2020.03.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
14 Sinha A, Singh V, Tandon R, Mohan Srivastava L. Dichotomy of complement system: Tumorigenesis or destruction. Immunol Lett 2020;223:89-96. [PMID: 32333965 DOI: 10.1016/j.imlet.2020.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Feng W, Wang Y, Chen S, Zhu X. Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer. Aging (Albany NY) 2020;12:24333-44. [PMID: 33259333 DOI: 10.18632/aging.202238] [Reference Citation Analysis]
16 van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol 2018;9:2134. [PMID: 30294326 DOI: 10.3389/fimmu.2018.02134] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 25.8] [Reference Citation Analysis]
17 Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in Multiple Myeloma. Cells 2020;9:E601. [PMID: 32138182 DOI: 10.3390/cells9030601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
18 Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PWHI, Valerius T. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. J I 2017;198:1585-94. [DOI: 10.4049/jimmunol.1601268] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
19 Olcina MM, Kim RK, Melemenidis S, Graves EE, Giaccia AJ. The tumour microenvironment links complement system dysregulation and hypoxic signalling. Br J Radiol 2019;92:20180069. [PMID: 29544344 DOI: 10.1259/bjr.20180069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Miller ML, Finn OJ. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods Enzymol 2020;632:431-56. [PMID: 32000909 DOI: 10.1016/bs.mie.2019.07.026] [Reference Citation Analysis]
21 Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest 2017;127:780-9. [PMID: 28248200 DOI: 10.1172/JCI90962] [Cited by in Crossref: 163] [Cited by in F6Publishing: 115] [Article Influence: 32.6] [Reference Citation Analysis]
22 Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, Li Y, Li J, Zhou B, Ye Y, Di C, Yu S, Zeng Y, Su S. Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. Cell 2020;180:1081-1097.e24. [PMID: 32142650 DOI: 10.1016/j.cell.2020.02.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 24.0] [Reference Citation Analysis]
23 Pinney JJ, Rivera-Escalera F, Chu CC, Whitehead HE, VanDerMeid KR, Nelson AM, Barbeau MC, Zent CS, Elliott MR. Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance. Blood 2020;136:2065-79. [PMID: 32556153 DOI: 10.1182/blood.2020005571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Daratumumab in multiple myeloma. Cancer 2019;125:2364-82. [PMID: 30951198 DOI: 10.1002/cncr.32065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
25 Hickey JW, Kosmides AK, Schneck JP. Engineering Platforms for T Cell Modulation. Int Rev Cell Mol Biol 2018;341:277-362. [PMID: 30262034 DOI: 10.1016/bs.ircmb.2018.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol 2021;18:805-28. [PMID: 32879472 DOI: 10.1038/s41423-020-00530-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
27 Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018;9:86-120. [PMID: 28822103 DOI: 10.1007/s13238-017-0457-8] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 30.2] [Reference Citation Analysis]
28 Zhang R, Liu Q, Peng J, Wang M, Gao X, Liao Q, Zhao Y. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Cell Death Dis 2019;10:836. [PMID: 31685825 DOI: 10.1038/s41419-019-2065-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
29 Bayón-Calderón F, Toribio ML, González-García S. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci 2020;21:E7685. [PMID: 33081391 DOI: 10.3390/ijms21207685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Kochanek DM, Ghouse SM, Karbowniczek MM, Markiewski MM. Complementing Cancer Metastasis. Front Immunol 2018;9:1629. [PMID: 30061895 DOI: 10.3389/fimmu.2018.01629] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
31 Gialeli C, Gungor B, Blom AM. Novel potential inhibitors of complement system and their roles in complement regulation and beyond. Mol Immunol 2018;102:73-83. [PMID: 30217334 DOI: 10.1016/j.molimm.2018.05.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
32 Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel mechanisms and functions of complement. Nat Immunol 2017;18:1288-98. [PMID: 29144501 DOI: 10.1038/ni.3858] [Cited by in Crossref: 200] [Cited by in F6Publishing: 192] [Article Influence: 40.0] [Reference Citation Analysis]
33 Bouwens van der Vlis TAM, Kros JM, Mustafa DAM, van Wijck RTA, Ackermans L, van Hagen PM, van der Spek PJ. The complement system in glioblastoma multiforme. Acta Neuropathol Commun 2018;6:91. [PMID: 30208949 DOI: 10.1186/s40478-018-0591-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
34 La-Beck NM, Islam MR, Markiewski MM. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine. Front Immunol 2020;11:603039. [PMID: 33488603 DOI: 10.3389/fimmu.2020.603039] [Reference Citation Analysis]
35 Sacchetti B, Botticelli A, Pierelli L, Nuti M, Alimandi M. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. Int J Mol Sci 2019;20:E1903. [PMID: 30999624 DOI: 10.3390/ijms20081903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
36 Li L, Yang H, Li Y, Li XD, Zeng TT, Lin SX, Zhu YH, Guan XY. Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression. Cell Death Discov 2018;4:63. [PMID: 29900010 DOI: 10.1038/s41420-018-0064-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Fishelson Z, Kirschfink M. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention. Front Immunol 2019;10:752. [PMID: 31024572 DOI: 10.3389/fimmu.2019.00752] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
39 Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk 2020;20:e752-68. [PMID: 32651110 DOI: 10.1016/j.clml.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
40 Popov J, Gilabert-oriol R, Bally MB. Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2017;117:256-69. [DOI: 10.1016/j.ejpb.2017.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel) 2020;9:E58. [PMID: 33126570 DOI: 10.3390/antib9040058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
42 Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT. Complement System: Promoter or Suppressor of Cancer Progression? Antibodies (Basel) 2020;9:E57. [PMID: 33113844 DOI: 10.3390/antib9040057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Elvington M, Liszewski MK, Atkinson JP. CD46 and Oncologic Interactions: Friendly Fire against Cancer. Antibodies (Basel) 2020;9:E59. [PMID: 33147799 DOI: 10.3390/antib9040059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]